COBAS 4800 HPV TEST, CE-IVD 05235901190

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a 01,05 report with the FDA on 2012-06-14 for COBAS 4800 HPV TEST, CE-IVD 05235901190 manufactured by Roche Molecular Systems.

Event Text Entries

[2728568] A customer from (b)(6) is alleging discrepant results were generated during a validation study using the kit cobas 4800 hpv amp/det 240t ce-ivd (m/n 05235901190; lot p05296) they identified 8 samples out of 120 that generated discrepant results. None of the results have been reported to physicians.
Patient Sequence No: 1, Text Type: D, B5


[9925713] A definitive conclusion cannot be drawn at this time, as the investigation into this issue is ongoing. The outcome of the investigation will be communicated through a follow-up report. The associated us product is m/n 05235880190. (b)(4).
Patient Sequence No: 1, Text Type: N, H10


[17353423] Type of report: follow up report 1. Type of follow-up: additional information / device evaluation. Device evaluated by manufacturer: yes. A customer from the (b)(6) stated that, while performing a validation study with the cobas 4800 hpv test, ce-ivd, they generated (b)(4) during the reproducibility section of the study. Five of the samples, sample ids ((b)(4)) generated ct values that were close to the limit of detection of the test, according to the package insert. Thus it is expected that these samples may waiver between negative and positive if retested. Sample ids (b)(4), tested on (b)(4) 2011, respectively, originally did not generate a ct value for the discrepant target. However, when retested on (b)(4) 2011, respectively, the samples generated a positive ct, within the normal range and not close to lod. This discrepancy may be due to cell clumping, where very heterogeneous samples may generate variations in ct values. Sample id (b)(4) generated overall inconsistent ct values. The ct values generated between testing on (b)(4) 2012, showed ct differences that can be expected in very heterogeneous samples. This discrepancy is also likely due to cell clumping or incomplete specimen mixing. Investigative testing of the customer returned samples generated results similar to those obtained by the customer. Retain testing of complaint kit batch p05296 met specification. The other kit batch n14750 expired before the customer complaint case was created and additional testing was not possible. The result discrepancies observed in the customer's validation study were due to sample specific issues. Five of the samples were close to lod and three of the samples may have had cell clumping or incomplete specimen mixing. There is no indication of a product non-conformance with the cobas 4800 hpv test. (b)(4).
Patient Sequence No: 1, Text Type: N, H10


MAUDE Entry Details

Report Number2243471-2012-00026
MDR Report Key2616051
Report Source01,05
Date Received2012-06-14
Date of Report2012-08-17
Date of Event2011-12-19
Date Mfgr Received2012-08-17
Date Added to Maude2012-10-11
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA0
Event Location0
Manufacturer ContactVINCENT STAGNITTO
Manufacturer Street1080 US HWY 202S
Manufacturer CityBRANCHBURG NJ 088763733
Manufacturer CountryUS
Manufacturer Postal088763733
Manufacturer Phone9082537569
Single Use0
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameCOBAS 4800 HPV TEST, CE-IVD
Generic NameKIT, DNA DETECTION, HUMAN PAPILLOMA VIRUS
Product CodeMAQ
Date Received2012-06-14
Catalog Number05235901190
Lot NumberP05296
Device Expiration Date2012-11-30
Device AgeDA
Device Eval'ed by MfgrY
Device Sequence No1
Device Event Key0
ManufacturerROCHE MOLECULAR SYSTEMS
Manufacturer Address1080 US HW 202S BRANCHBURG NJ 08876373 US 08876 3733


Patients

Patient NumberTreatmentOutcomeDate
10 2012-06-14

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.